glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results could be 'practice changing' for adults with diabetes, CKD Kidney and Cardiovascular Outcomes Among
Description
The trial, which was funded by AstraZeneca, tested different starting doses, dose-escalation schemes, and maintenance doses over a 26-week period
Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes
Overcoming these challenges could lead to long-term healthcare savings and improved overall health outcomes
- Could success in dermatomyositis pave the way for expansion into other inflammatory diseases
GLP-1RAs prevent post-MI remodeling by having an impact on the extracellular matrix changes rather than dependency on its glycemic control [76]
